Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113.7 USD | -0.88% | +9.03% | -18.34% |
Jun. 06 | TD Cowen Adjusts Price Target on Illumina to $122 From $140 | MT |
Jun. 05 | Nephron Research Upgrades Illumina to Hold, Price Target at $100 | MT |
Evolution of the average Target Price on Illumina, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Illumina, Inc.
TD Cowen | |
Nephron Research | |
Jefferies & Co. | |
Daiwa Securities | |
Bernstein | |
Baird | |
Evercore ISI | |
Leerink Partners | |
HSBC | |
Baptista Research | |
RBC Capital Markets | |
OTR Global | |
UBS | |
Stifel Nicolaus | |
Barclays | |
Citigroup | |
Scotiabank | |
Stephens Inc. | |
BofA Securities | |
Canaccord Genuity | |
Piper Sandler | |
JPMorgan Chase | |
Credit Suisse | |
SVB Securities LLC | |
Argus | |
Morgan Stanley | |
Cowen | |
SVB Leerink | |
BTIG | |
Wells Fargo Securities | |
Atlantic Equities |
EPS Revisions
- Stock Market
- Equities
- ILMN Stock
- Consensus Illumina, Inc.